Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.14−0.24 (-10.08%)
Close on Nov 12, 2026Market cap $328.66MP/E –Yield –
Editas Medicine price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Editas Medicine's price to book ratio was 2.2× on Nov 11, 2026, against 16.7× a year earlier. Over the last 5 years it ranged from 0.6× to 76.8×, with a median of 1.9×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.2× | −12.0 |
| 2025 | Dec 31, 2025 | 14.2× | +13.6 |
| 2024 | Dec 31, 2024 | 0.6× | −1.7 |
| 2023 | Dec 29, 2023 | 2.3× | +0.8 |
| 2022 | Dec 30, 2022 | 1.5× | −1.6 |
| 2021 | Dec 31, 2021 | 3.1× | −6.8 |
| 2020 | Dec 31, 2020 | 9.9× | +2.7 |
| 2019 | Dec 31, 2019 | 7.2× | +2.4 |
| 2018 | Dec 31, 2018 | 4.8× | −2.4 |
| 2017 | Dec 29, 2017 | 7.2× | +3.8 |
| 2016 | Dec 30, 2016 | 3.4× | – |
See a number that looks wrong?